Massachusetts health care law expected to improve access to clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Massachusetts Governor Charlie Baker signed into law a compromise healthcare bill that calls for reimbursing cancer patients for the out-of-pocket expenses associated with clinical trial participation and creating across the board reimbursement programs in the state.

The anticipated result is that thousands of cancer patients in Massachusetts will gain access to advanced treatments offered in clinical trials. The goal is to improve participation and retention in cancer clinical trials, especially among underserved populations.

The legislative action is the result of an effort by Lazarex Cancer Foundation and members of the state legislature, including Representative Hannah Kane, the author and lead on the cancer trial language, Leader Ronald Mariano, former Senator Richard Ross, and others, to bring attention to the issue. Co-authored by Lazarex, the legislation clarifies that reimbursing patients for the out-of-pocket expenses necessary to travel to a clinical trial site are not to be considered inducements or coercion.

Similar legislation is being considered in Florida, and New Mexico, and is already law in California, Pennsylvania, Texas, Illinois and Wisconsin.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login